211 related articles for article (PubMed ID: 25760299)
1. Interleukin-6 in rheumatoid arthritis - from the laboratory to the bedside.
Liu X; Teichtahl AJ; Wicks IP
Curr Pharm Des; 2015; 21(17):2187-97. PubMed ID: 25760299
[TBL] [Abstract][Full Text] [Related]
2. IL-6 inhibitors for treatment of rheumatoid arthritis: past, present, and future.
Kim GW; Lee NR; Pi RH; Lim YS; Lee YM; Lee JM; Jeong HS; Chung SH
Arch Pharm Res; 2015; 38(5):575-84. PubMed ID: 25648633
[TBL] [Abstract][Full Text] [Related]
3. New biologics for rheumatoid arthritis.
Choy E
J R Coll Physicians Edinb; 2011 Sep; 41(3):234-7. PubMed ID: 21949922
[TBL] [Abstract][Full Text] [Related]
4. IL-6 inhibition for the treatment of rheumatoid arthritis and other conditions.
Woodrick RS; Ruderman EM
Bull NYU Hosp Jt Dis; 2012; 70(3):195-9. PubMed ID: 23259628
[TBL] [Abstract][Full Text] [Related]
5. Targeting IL-6 or IL-6 Receptor in Rheumatoid Arthritis: What's the Difference?
Avci AB; Feist E; Burmester GR
BioDrugs; 2018 Dec; 32(6):531-546. PubMed ID: 30488231
[TBL] [Abstract][Full Text] [Related]
6. Biologic agents for rheumatoid arthritis: 2008 and beyond.
Sweiss NJ; Hushaw LL
J Infus Nurs; 2009; 32(1 Suppl):S4-17; quiz S19-24. PubMed ID: 19142153
[TBL] [Abstract][Full Text] [Related]
7. A novel scoring system based on common laboratory tests predicts the efficacy of TNF-inhibitor and IL-6 targeted therapy in patients with rheumatoid arthritis: a retrospective, multicenter observational study.
Nakagawa J; Koyama Y; Kawakami A; Ueki Y; Tsukamoto H; Horiuchi T; Nagano S; Uchino A; Ota T; Akahoshi M; Akashi K
Arthritis Res Ther; 2017 Aug; 19(1):185. PubMed ID: 28800780
[TBL] [Abstract][Full Text] [Related]
8. Profile of sarilumab and its potential in the treatment of rheumatoid arthritis.
Raimondo MG; Biggioggero M; Crotti C; Becciolini A; Favalli EG
Drug Des Devel Ther; 2017; 11():1593-1603. PubMed ID: 28579757
[TBL] [Abstract][Full Text] [Related]
9. Tumor necrosis factor blockade differentially affects innate inflammatory and Th17 cytokines in rheumatoid arthritis.
Zivojinovic SM; Pejnovic NN; Sefik-Bukilica MN; Kovacevic LV; Soldatovic II; Damjanov NS
J Rheumatol; 2012 Jan; 39(1):18-21. PubMed ID: 22133625
[TBL] [Abstract][Full Text] [Related]
10. Proinflammatory cytokines synergistically enhance the production of chemokine ligand 20 (CCL20) from rheumatoid fibroblast-like synovial cells in vitro and serum CCL20 is reduced in vivo by biologic disease-modifying antirheumatic drugs.
Kawashiri SY; Kawakami A; Iwamoto N; Fujikawa K; Aramaki T; Tamai M; Arima K; Kamachi M; Yamasaki S; Nakamura H; Tsurumoto T; Kono M; Shindo H; Ida H; Origuchi T; Eguchi K
J Rheumatol; 2009 Nov; 36(11):2397-402. PubMed ID: 19797510
[TBL] [Abstract][Full Text] [Related]
11. IL-6 inhibitor for the treatment of rheumatoid arthritis: A comprehensive review.
Ogata A; Kato Y; Higa S; Yoshizaki K
Mod Rheumatol; 2019 Mar; 29(2):258-267. PubMed ID: 30427250
[TBL] [Abstract][Full Text] [Related]
12. Drug survival, efficacy and toxicity of monotherapy with a fully human anti-tumour necrosis factor-alpha antibody compared with methotrexate in long-standing rheumatoid arthritis.
Barrera P; van der Maas A; van Ede AE; Kiemeney BA; Laan RF; van de Putte LB; van Riel PL
Rheumatology (Oxford); 2002 Apr; 41(4):430-9. PubMed ID: 11961174
[TBL] [Abstract][Full Text] [Related]
13. Clinical experience with inhibition of interleukin-6.
Choy E
Rheum Dis Clin North Am; 2004 May; 30(2):405-15, viii. PubMed ID: 15172049
[TBL] [Abstract][Full Text] [Related]
14. Lipid profile of rheumatoid arthritis patients treated with anti-tumor necrosis factor-alpha drugs changes according to disease activity and predicts clinical response.
Cacciapaglia F; Anelli MG; Rinaldi A; Serafino L; Covelli M; Scioscia C; Iannone F; Lapadula G
Drug Dev Res; 2014 Nov; 75 Suppl 1():S77-80. PubMed ID: 25381986
[TBL] [Abstract][Full Text] [Related]
15. Tumour necrosis factor α antagonists in the treatment of rheumatoid arthritis: an immunological perspective.
Meroni PL; Valesini G
BioDrugs; 2014 Apr; 28 Suppl 1():S5-13. PubMed ID: 24687234
[TBL] [Abstract][Full Text] [Related]
16. [Treatment of rheumatoid arthritis by inhibition of tumor necrosis factor with infliximab or etanercept].
Tijhuis GJ; van de Putte LB; Breedveld FC
Ned Tijdschr Geneeskd; 2001 Sep; 145(39):1880-5. PubMed ID: 11605312
[TBL] [Abstract][Full Text] [Related]
17. Safety and efficacy of disease-modifying anti-rheumatic agents: focus on the benefits and risks of etanercept.
Fleischmann R; Iqbal I; Nandeshwar P; Quiceno A
Drug Saf; 2002; 25(3):173-97. PubMed ID: 11945114
[TBL] [Abstract][Full Text] [Related]
18. Rheumatoid Arthritis - Anti-TNF.
Chaabo K; Kirkham B
Int Immunopharmacol; 2015 Aug; 27(2):180-4. PubMed ID: 25962818
[TBL] [Abstract][Full Text] [Related]
19. Emerging biologic drugs for the treatment of rheumatoid arthritis.
Puppo F; Murdaca G; Ghio M; Indiveri F
Autoimmun Rev; 2005 Nov; 4(8):537-41. PubMed ID: 16214092
[TBL] [Abstract][Full Text] [Related]
20. Synovial fluid IL-6 concentrations associated with positive response to tocilizumab in an RA patient with failed response to anti-TNF and rituximab.
Wright HL; Mewar D; Bucknall RC; Edwards SW; Moots RJ
Rheumatology (Oxford); 2015 Apr; 54(4):743-4. PubMed ID: 25667432
[No Abstract] [Full Text] [Related]
[Next] [New Search]
